Sanofi: fast-track procedure granted for Dupixent

(CercleFinance.com) - Sanofi announced on Monday morning that the FDA has granted Breakthrough Therapy designation (allowing it to benefit from a fast-track procedure) to Dupixent, for the treatment of eosinophilic esophagitis.


"Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE). There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients' ability to swallow and eat," Sanofi said.


Copyright (c) 2020 CercleFinance.com. All rights reserved.